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Abstract
Background: Non-organ-specific autoantibodies are present in centenarians without evidence of autoimmune diseases but conflicting or
no data on anti-phospholipid and anti-phospholipid binding proteins were reported.
Objective: To investigate the presence and antigen specificity of anti-phospholipid and anti-phospholipid binding proteins in centenarians.
Methods: Seventy-seven centenarians, 70 adult controls, 65 unselected elderly subjects, and 38 old SENIEUR volunteers were
investigated. Anti-cardiolipin, anti-human b2glycoprotein I, and lupus anticoagulant were detected. Antigen specificity was assayed against
plates coated with anionic, neutral and cationic phospholipids and b2glycoprotein I-dependence was also evaluated.
Results: 54.3% of the centenarians were positive for IgG and 8.6% for IgM anti-b2glycoprotein I antibodies, while only 20.7%
centenarians were positive for anti-cardiolipin IgG and 2.59% for IgM; none resulted positive for lupus anticoagulant. Anti-cardiolipin
positive sera cross-reacted with negatively charged phospholipids and displayed decreased binding to serum-free cardiolipin-coated plates
that was restored by human b2glycoprotein I or fetal calf serum.
Conclusions: Centenarians display high reactivity against human b2glycoprotein I but low binding to the bovine molecule in the anti-
cardiolipin assay. In spite of the presence of antibodies comparable to those found in patients with the anti-phospholipid syndrome, no
vascular events were reported suggesting the presence of unknown protective factors and/or the lack of triggering factors.
q 2004 Elsevier Inc. All rights reserved.
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Centenarians display a characteristic autoantibody
profile, being organ-specific autoantibodies absent and
non-organ-specific autoantibodies increased without any
full-blown autoimmune disease (Mariotti et al., 1992;
Candore et al., 1997). In addition, non-organ-specific
autoantibodies increase with age, but it is still debated
whether aPL are also produced and associated with the
clinical manifestations of the APS (Candore et al., 1997;
Piette and Cacoub, 1998; Levine et al., 2004).Experimental Gerontology 39 (2004) 1459–1465www.elsevier.com/locate/expgero
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group of autoantibodies diagnosed as LA or aCL, associated
with recurrent thrombosis, pregnancy loss, thrombocytope-
nia and thought to be pathogenic (Levine et al., 2002).
Rather than to be directed against PLs only, these antibodies
are specific for PL-binding protein (Levine et al., 2002;
Meroni and Riboldi, 2001; de Groote et al., 2002; Roubey,
2000). Among them, b2GPI does represent the most
important one (de Groote et al., 2002). It has been widely
accepted that aCL detectable in APS require the presence of
serum PL-binding proteins, mainly b2GPI, when detected
by solid-phase assay (Levine et al., 2002; Meroni and
Riboldi, 2001; de Groote et al., 2002; Roubey, 2000). Such
an antigen specificity does allow to distinguish them from
aPL occurring in infectious diseases which are not usually
associated with the clinical manifestations of the syndrome
(Levine et al., 2002). In this regard, there is no information
on the aPL antigen specificity in centenarians and no data on
the occurrence of anti-b2GPI autoantibodies in these
subjects (Candore et al., 1997).
Interestingly, centenarians have an increased prevalence
of high-risk genetic markers of hypercoagulability (Mari et
al., 1995; Mannucci et al., 1997), and are paradoxically
characterized by low HDL-cholesterol and relatively high
triglyceride levels, which together are considered to be
strong risk factors for atherothrombosis (Baggio et al.,
1998). It has been suggested that protective mechanisms
might counteract these risk factors, allowing them to age
successfully and to escape major thrombotic diseases
(Baggio et al., 1998).
Taking into account the age-associated immune dysfunc-
tion leading to autoimmunity, we investigated the presence
of aPL in a total of 250 individuals of different ages,
including 77 centenarians. We also characterized the
antibodies, in order to assess whether the lack of thrombotic
events in these subjects can be related to the antibody
antigen specificity or to the paradoxical status that does not
induce thrombosis in centenarians in spite of the presence of
factors that are risk factors for the general population.2. Materials and methods
2.1. Subjects and patients
A total of 250 individuals living in Northern Italy were
studied: nZ77 centenarians [20 males and 57 females, age
102G1.5 years (meanGSD); group 1]; nZ70 randomly
selected, apparently healthy, young control subjects
[23 males and 47 females, age 35.8G9.3 years (group 2)];
nZ65 unselected elderly subjects [31 males and 34 females,
age 70.2G5.3 years (group 3)]; and 38 old volunteers [14
males and 24 female, age 70.9G4.3 years (group 4)]
selected according to the SENIEUR Protocol (Ligthart et al.,
1984). Centenarians were selected according to the
classification proposed by Franceschi et al. (2000).APS patients were diagnosed according to the Sapporo’s
criteria (Wilson et al., 1999).
Approval for these studies were obtained from the
Institutional Revue Board of the University of Milan and
informed consent was obtained according to Declaration of
Helsinki.
2.2. Anti-phospholipid antibodies
aCL were detected by ELISA and values expressed as
IgG/IgM aPL Units (GPL/MPL, respectively; values were
considered positive when O10 GPL or MPL) or as low,
medium and high positivities as described (Tincani et al.,
2001).
Anti-anionic (PS), -neutral (PE, PC), -cationic PL (Sph)
activity was evaluated by ELISA as described (Allegri et al.,
1990; Tincani et al., 1996; Di Simone et al., 2000).
b2GPI was purified from NHS, and anti-b2GPI anti-
bodies were detected by ELISA as described (Tincani et al.,
1996; Di Simone et al., 2000; Balestrieri et al., 1995). Sera
were considered positive if OD values were higher than the
95th percentile of 50 normal healthy controls (0.130 for IgG
and 0.280 for IgM, respectively).
To evaluate the b2GPI-dependence of aCL positive sera,
aCL assays were performed in the absence of FCS, using
gelatin only (0.5%; Sigma-Aldrich) in the blocking buffer as
well as after addition of human b2GPI (5 mg/ml) or FCS
(10%) as described (Di Simone et al., 2000).
2.3. Lupus anticoagulant
LA was detected by activated thromboplastin time and
by Kaolin clotting time carried out with 0.2% kaolin
suspension in saline (Exner et al., 1978).
2.4. Statistical analysis
The association with abnormally high aPL levels were
evaluated in logistic regression. Odds ratios and 95%
confidence intervals (CIs) were reported in centenarians,
young healthy subjects, unselected elderly subjects and old
SENIEUR volunteers.3. Results
3.1. Prevalence of aCL and LA in centenarians
Fig. 1 shows the values of IgG (Fig. 1A) and IgM
(Fig. 1B) aCL in the different groups. Sixteen out of 77
(20.7%) centenarians displayed IgG positivities in compari-
son to 0/70 in young healthy subjects, 3/65 (4.6%) in
unselected elderly subjects and 4/38 (10.5%) in the old
SENIEUR volunteers, respectively. The association with
IgG aCL was significantly higher (pZ0.0001) in centenar-
ians than in young healthy subjects and in unselected elderly
Fig. 1. Prevalence of IgG (A) and IgM (B) aCL in centenarians and control groups: (1) centenarians; (2) healthy young subjects; (3) unselected elderly subjects;
(4) old volunteers, selected according to the SENIEUR Protocol (13). The dashed line indicates the cut off limit of normal values; the mean values are
represented by horizontal lines. Values are expressed as GPL or MPL units.
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tended to be higher than in old SENIEUR volunteers [pZ
0.140 (Odds ratio 2.4 CI 95% 0.7–7.7)]. Two samples only
from centenarians resulted positive for IgM aCL.
Fifty-nine plasmas were available for LA evaluation and
all resulted negative. Ten out of these 59 samples resulted
positive in the IgG aCL assay (8/10 low and 2/10 medium
positive).3.2. Antigen characterization of aCL in centenarians
Samples positive for IgG aCL from centenarians have
been tested against plates coated with PL with different
electric charges. Table 1 shows representative results of 10
selected sera (six positive and four negative for IgG aCL)
against plates coated with anionic (PS), cationic (Sph) and
neutral (PE, PC) PLs. Samples negative for aCL did not
display any binding even to plates coated with other anionic
PLs. While all the aCL positive sera reacted with negativelyTable 1
IgG aCL positive sera from centenarians display a cross-reactivity with anionic p
Subject Anti-CL Anti-PS A
IgG Ig
1 97 0.980G0.152 0
2 12 0.324G0.101 0
3 19 0.452G0.115 0
4 16 0.402G0.102 0
5 54 0.758G0.161 0
6 10 0.284G0.022 0
7 4 0.123G0.098 0
8 3 0.106G0.047 0
9 5 0.078G0.021 0
10 7 0.111G0.075 0
Values are expressed in GPL units for aCL and in OD values (meanGSD of trip
Normal values for anti-PS, anti-PE, anti-PC and anti-Sph antibodies were, respe
human sera). Positive results are typed in bold.(PS), only few displayed borderline reactivity with neutral
(PE, PC) and none with positively (Sph) charged molecules.
One serum from centenarians positive also for IgM aCL (24
MPL) displayed a binding activity to PS (0.421 OD value;
meanC3SD of 50 normal controlsZ0.198 OD value). The
remaining aCL positive sera from centenarians displayed
comparable results (data not shown). As previously
reported, sera from APS patients reacted with plates coated
with anionic but not with neutral or positive PLs (data not
shown) (Di Simone et al., 2000; Harris et al., 1985).
Forty-six sera from centenarians have been tested for
anti-human b2GPI IgG and IgM antibodies; 25/46 (54.3%)
and 4/46 (8.6%) sera, respectively, displayed IgG and IgM
anti-b2GPI values higher than the normal controls. Only
4/38 (10.5%) old SENIEUR volunteers displayed low anti-
b2GPI IgG positivities (lower than 0.320 OD values), while
just one unselected elderly subject resulted borderline
positive; no positivities for IgM anti-b2GPI antibodies
were found (data not shown). Fig. 2 shows the analyticalhospholipids
nti-PC Anti-PE Anti-Sph
G IgG IgG
.231G0.02 0.201G0.05 0.001G0.001
.041G0.04 0.05G0.02 0.021G0.05
.092G0.005 0.06G0.02 0.034G0.02
.045G0.002 0.101G0.03 0.025G0.02
.157G0.04 0.197G0.01 0.017G0.01
.035G0.03 0.04G0.03 0.028G0.01
.161G0.054 0.191G0.045 0.187G0.052
.120G0.085 0.154G0.074 0.162G0.068
.157G0.079 0.098G0.021 0.097G0.031
.115G0.073 0.078G0.052 0.140G0.075
licate experiments) for anti-PS, anti-PC, anti-PE and anti-Sph antibodies.
ctively, lower than 0.154, 0.194, 0.197, 0.201 (meanC3 SD of 50 normal
Fig. 2. Anti-cardiolipin and anti-human b2GPI IgG antibodies in sera from
centenarians. Values are expressed as GPL units or as OD!10K3 values.
The dashed lines indicate the cut off limit of normal values (10 GPL for aCL
and 0.130 OD for anti-b2GPI assay, respectively).
Fig. 3. Beta 2GPI-dependence of IgG and IgM binding to CL-coated plates of re
dilutions of sera have been tested on serum-free CL-coated plates in the presence (
The values are expressed as GPL or MPL units.
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samples reacted with human b2GPI but not with CL-coated
plates and the reactivity against b2GPI was high in almost
half of the samples. Only two out of four IgM anti-b2GPI
positive sera also tested positive in the aCL assay (data not
shown).
The presence of a reactivity against human b2GPI
suggests a cofactor dependence for the aCL activity detected
in centenarians. In order to demonstrate such a dependence,
two positive samples from APS patients or from aCL positive
centenarians (two IgG positive and one IgM positive) were
tested with plates blocked with human b2GPI or with gelatin.
The binding activity of the sera from centenarians declined
when tested on plates without b2GPI (i.e. blocked with
gelatin), and the binding was restored by the addition of
purified human b2GPI (5 mg/ml) in a manner quite
comparable to that found with the two APS reference sera.
Fig. 3 shows the results of representative samples. Exper-
iments carried out with the addition of FCS (10%) as source
of bovine b2GPI gave comparable results (data not shown).presentative sera from centenarians (A) and from APS patients (B). Serial
–%–) (5 mg/ml) or in the absence (–&–) of b2GPI as described in Section 2.
P.L. Meroni et al. / Experimental Gerontology 39 (2004) 1459–1465 14634. Discussion
Our results report for the first time a high prevalence of
anti-human b2GPI antibodies in centenarians in good health
without any clinical manifestation of APS.
Anti-b2GPI antibodies have been recently found to be an
apparently more specific, although less sensitive, diagnostic
tool for the APS, and to represent an antibody population
able to mediate potential pathogenic mechanisms in APS
(Levine et al., 2002; Meroni and Riboldi, 2001; Tincani
et al., 1998). Moreover, some authors reported that a small
but consistent number of patients mirroring a full-blown
APS can display antibody against the human b2GPI only,
without any cross-reactivity with molecules from other
species (Cabral et al., 1996). The lack of reactivity against
bovine b2GPI was suggested to explain why these patients
were negative in the standard assay for aCL antibodies,
where bovine b2GPI supplied by FCS is the major target
antigen for aPL assay (Levine et al., 2002; Meroni and
Riboldi, 2001; de Groote et al., 2002; Roubey, 1999, 2000).
Accordingly, centenarians displayed a high prevalence of
antibodies by using human b2GPI-coated plates but lower
prevalence and titres of positive results when the same sera
were assayed by the standard aCL assay that employs
bovine serum as blocking agent. This finding does suggest
that centenarians react with a much more specificity for the
human molecule.
It has been widely accepted that aPL detectable in APS
display a cross-reactivity with anionic PLs and such a
reactivity was suggested to be the result of the binding of the
cationic b2GPI to the negatively charged PLs (Roubey,
1999, 2000). Once bound, b2GPI expresses new cryptic
epitopes specific for the autoantibodies and/or displays an
increased antigen density that is required because of the low
affinity of the anti-b2GPI autoantibodies (de Groote et al.,
2002; Roubey, 1999, 2000). In line with these findings, a
strong reactivity with plates coated with anionic, but
negligible with cationic and absent with neutral PLs, was
found in sera from centenarians, as reported in APS.
To further support the ‘autoimmune’ nature of the aPL
detectable in our subjects, we investigated whether the aCL
positive sera bound to CL-coated plates in a b2GPI-
dependent manner as reported for APS sera. Our data
clearly show that the aCL assay carried out in serum-free
buffer displayed decreased binding values, and that the
reactivity was restored if human purified b2GPI or FCS, as
source of bovine b2GPI, were supplied.
Altogether our data suggest that centenarians react
preferentially with human b2GPI but that the presence of
a cross-reactivity with bovine b2GPI appears to be also
responsible for the less frequent positivities in the standard
aCL assay.
In the APS, the breakdown of the tolerance towards the
self b2GPI has been suggested to be the result of a
molecular mimicry between exogenous and self molecules,
at least in part due to the wide aminoacid homology ofb2GPI from different species (Matsuura et al., 1991; Tincani
et al., 2002; Gharavi et al., 1999; Blank et al., 2002). Still
debated is the initial trigger of the response against the
b2GPI, although preliminary data suggest that bacterial and/
or viral peptides sharing common aminoacid sequences
could be responsible (Gharavi et al., 1999; Blank et al.,
2002).
It is useful to speculate on the possible mechanisms that
could support the appearance of an anti-b2GPI activity in
centenarians. Lifelong exposure to self molecules resulting
from the continuous apoptosis occurring in the body, an
event particularly consistent in centenarians (Aggarwal and
Gupta, 1998), may contribute to this phenomenon. In
particular, apoptotic blebs were reported to expose anionic
PL (mainly PS) that in turn are able to bind circulating
b2GPI (Casciola-Rosen et al., 1996). Such an event results
in the exposure of epitopes on the bound molecule that are
able to induce an anti-b2GPI humoral immune response in
naı¨ve mice (Price et al., 1996). So, it could be possible that
the increased exposure of b2GPI on apoptotic cells might
act as a persistent immunogenic stimulus which could end
into an antibody response against the self molecule.
Alternatively, it has been also reported that b2GPI bound
to oxLDL can be recognized by specific antibodies,
suggesting that even in this case, the molecule can display
the right immunogenic epitopes (Hasunuma et al., 1997).
Furthermore, increased plasma levels of oxLDL have been
found in centenarians (Maggi et al., 1993), so offering large
amounts of substrates able to bind b2GPI and to make the
right immunogenic epitopes available to the immune
system.
Whatever the mechanisms by which centenarians elicit
an anti-b2GPI response comparable to that found in APS,
the clinical records of our subjects do not have any evidence
of the manifestations associated with the presence of such
autoantibodies.
The lack of clinical manifestations might be related to the
absence of LA, and to the fact that most of the aCL positive
sera in centenarians were at low titre. Actually, it is widely
accepted that LA does represent the strongest risk factor for
thrombotic events in APS while medium/high aCL titers are
closer associated with clinical events than low titres (Levine
et al., 2002; Galli et al., 2003). However, such an
explanation does not account for the absence of thrombotic
events in centenarians with medium or high titres of b2GPI-
dependent aCL.
Anti-phospholipid antibodies are now considered patho-
genic autoantibodies rather than a simple serological marker
for APS. Several potential mechanisms have been reported
to explain the aPL ability to induce thrombosis and/or fetal
loss (Meroni and Riboldi, 2001). However, aPL alone
apparently are unable to induce thrombotic manifestations
per se. In this regard, a two-hit hypothesis has been
suggested: aPL (first hit) increases the risk of thrombotic
events that occur in the presence of another thrombophilic
condition (second hit). In line with such a hypothesis are
P.L. Meroni et al. / Experimental Gerontology 39 (2004) 1459–14651464the experimental findings in murine models, in which
infusion of aPL can increase clotting after mechanical injury
to the vessel wall but do not induce thrombus when injected
into uninjured vessels (Pierangeli et al., 2000). Moreover,
the two hit hypothesis might also explain why patients
persistently positive for aPL do display thrombotic events
only occasionally. In this regard, the positivity for aPL with
‘autoimmune’ characteristics and the concurrent presence of
additional risk factors for thrombosis (i.e. hypercoagul-
ability, factor V mutation, polymorphism 4G4G of PAI-I
promoter, G20210A prothrombin mutation, dyslipidemia)
(Mari et al., 1995, 1996; Mannucci et al., 1997; Sacchi et al.,
1999; Baggio et al., 1998) in centenarians should favour the
appearance of the vascular manifestations of the syndrome.
Moreover, we found high plasma levels of pro-inflamma-
tory cytokines, such as IL-6, and low levels of anti-
inflammatory cytokines, such as IL-10, in centenarians
(Bonafe` et al., 2001). Pro-inflammatory cytokines might
activate monocytes and/or endothelial cells favouring the
induction of a pro-coagulant phenotype (Cines et al., 1998;
Bouchard and Tracy, 2001) and acting as additional ‘second
hit’ risk factors. Nevertheless, all the subjects of our series
escaped major thrombotic diseases. Thus, it is useful to
speculate that in centenarians yet unknown mechanisms are
active in protecting the thrombophilic state associated to
aPL or that in the oldest old, the risk factors could play a
different role than in young-adult subjects. Actually, high
total cholesterol concentrations have been associated with
longevity owing to lower mortality from cancer and
infection (Weverling-Rijnsburger et al., 1997).
Further studies aimed to clarify and disentangle such
mechanisms could offer new insight to better understand not
only the biology of ageing but also the pathophysiology of
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